Abstract
The natural progression of the severe form of mucopolysaccharidosis II in children is a rapid decline of neurodevelopmental function with hydrocephalus. Recombinant human iduronate-2-sulfatase enzyme replacement therapy (ERT) under a standard regimen seems to have limited effect. Therefore, we determined whether early, high-dose ERT attenuated ventriculomegaly and histologic abnormalities in the brains of IdS-knockout mice. IdS-knockout mice received saline or recombinant human IdS (0.5/1.0/2.0 mg kg−1) intravenously once weekly, starting at 4 weeks of age and continuing until 20 weeks. ERT with 2.0 mg kg−1, but not 0.5 or 1.0 mg kg−1, significantly attenuated enlarged ventricles, as confirmed by in vivo 7-teslar brain magnetic reasonance image (MRI) at 20 weeks. However, neuronal cytoplasmic vacuolization and morphological alteration in the purkinje cells on brain histology and glycosaminoglycan (GAG) levels in brain homogenates were reduced in mice receiving ERT at lower dose than 2.0 mg kg−1. Additionally, GAG levels significantly correlated with the percent volume ratio of ventricle to whole brain. These results suggested that high-dose systemic ERT started early in life could be a promising therapeutic modality for improving neurologic dysfunction including ventriculomegaly in children with severe Hunter syndrome.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Martin, R., Beck, M., Eng, C., Giugliani, R., Harmatz, P., Munoz, V. et al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 121, e377–e386 (2008).
Cho, Y. S., Kim, J. H., Kim, T. W., Chung, S. C., Chang, S. A. & Jin, D. K. Otologic manifestations of Hunter syndrome and their relationship with speech development. Audiol Neurootol 13, 206–212 (2008).
Jung, S. C., Park, E. S., Choi, E. N., Kim, C. H., Kim, S. J. & Jin, D. K. Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vector-mediated gene therapy. Mol. Cells. 30, 13–18 (2010).
Lee, J. H., Choe, Y. H., Kim, S. J., Paik, K. H. & Jin, D. K. Changes in glycogen and glycosaminoglycan levels in hepatocytes of iduronate-2-sulfatase knockout mice before and after recombinant iduronate-2-sulfatase supplementation. Yonsei. Med. J. 52, 263–267 (2011).
Hong, S. H., Chu, H., Kim, K. R., Ko, M. H., Kwon, S. Y., Moon, I. J. et al. Auditory characteristics and therapeutic effects of enzyme replacement in mouse model of the mucopolysaccharidosis (MPS) II. Am. J. Med. Genet. A. 158A, 2131–2138 (2012).
Holt, J. B., Poe, M. D. & Escolar, M. L. Natural progression of neurological disease in mucopolysaccharidosis type II. Pediatrics 127, e1258–e1265 (2011).
Muenzer, J., Wraith, J. E., Beck, M., Giugliani, R., Harmatz, P., Eng, C. M. et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet. Med. 8, 465–473 (2006).
Wang, R. Y., Cambray-Forker, E. J., Ohanian, K., Karlin, D. S., Covault, K. K., Schwartz, P. H. et al. Treatment reduces or stabilizes brain imaging abnormalities in patients with MPS I and II. Mol. Genet. Metab. 98, 406–411 (2009).
Higuchi, T., Shimizu, H., Fukuda, T., Kawagoe, S., Matsumoto, J., Shimada, Y. et al. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II. Mol. Genet. Metab. 107, 122–128 (2012).
Polito, V. A., Abbondante, S., Polishchuk, R. S., Nusco, E., Salvia, R. & Cosma, M. P. Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy. Hum. Mol. Genet. 19, 4871–4885 (2010).
Fan, Z., Styner, M., Muenzer, J., Poe, M. & Escolar, M. Correlation of automated volumetric analysis of brain MR imaging with cognitive impairment in a natural history study of mucopolysaccharidosis II. AJNR. Am. J. Neuroradiol. 31, 1319–1323 (2010).
Gundersen, H. J. & Jensen, E. B. The efficiency of systematic sampling in stereology and its prediction. J. Microsc. 147, 229–263 (1987).
Vogler, C., Levy, B., Grubb, J. H., Galvin, N., Tan, Y., Kakkis, E. et al. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc. Natl. Acad. Sci. USA 102, 14777–14782 (2005).
Garcia, A. R., Pan, J., Lamsa, J. C. & Muenzer, J. The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome). J. Inherit. Metab. Dis. 30, 924–934 (2007).
Polito, V. A. & Cosma, M. P. IDS crossing of the blood-brain barrier corrects CNS defects in MPSII mice. Am. J. Hum. Genet. 85, 296–301 (2009).
Sohn, Y. B., Lee, J., Cho, S. Y., Kim, S. J., Ko, A. R., Nam, M. H. et al. Improvement of CNS defects via continuous intrathecal enzyme replacement by osmotic pump in mucopolysaccharidosis type II mice. Am. J. Med. Genet. A. 161A, 1036–1043 (2013).
Garcia, A. R., DaCosta, J. M., Pan, J., Muenzer, J. & Lamsa, J. C. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II. Mol. Genet. Metab. 91, 183–190 (2007).
Zareba, G. Idursulfase in Hunter syndrome treatment. Drugs of today 43, 759–767 (2007).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ahn, S., Chang, Y., Sung, D. et al. High-dose enzyme replacement therapy attenuates cerebroventriculomegaly in a mouse model of mucopolysaccharidosis type II. J Hum Genet 58, 728–733 (2013). https://doi.org/10.1038/jhg.2013.92
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/jhg.2013.92
Keywords
This article is cited by
-
Effect of systemic high dose enzyme replacement therapy on the improvement of CNS defects in a mouse model of mucopolysaccharidosis type II
Orphanet Journal of Rare Diseases (2015)
-
A commentary on high-dose enzyme replacement therapy attenuates cerebroventriculomegaly in a mouse model of mucopolysaccharidosis type II
Journal of Human Genetics (2013)
